In the News

395 News Items found
MSK acupuncturist Charles Rico is seen giving acupressure to patient Elizabeth Sosa at the MSK Ralph Lauren Center.
Learn how acupuncture is being used at the MSK Ralph Lauren Center in Harlem to reduce pain and other symptoms in people facing cancer.
Dr. Michael Overholtzer
Feature
Seventeen scientists are poised to receive their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Their years of dedication and training will be recognized on May 17, 2023, as part of Memorial Sloan Kettering’s 44th annual academic convocation.
Through-the-microscope view of a tissue sample
New MSK research identified a way to reduce toxicity in CAR T cell therapy; discovered a division of labor in DNA repair that suggests a possible therapeutic strategy for certain cancers; developed a new method to enable imaging of two PET tracers simultaneously; found biomarkers that could help predict outcomes in HER2-positive metastatic esophagogastric cancer; and made progress toward improving options for patients with early-stage, potentially indolent cancers.
A liquid being pipetted into a well plate.
Fifteen young scientists are poised to receive their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Their years of dedication and training will be recognized on May 13, 2026, as part of Memorial Sloan Kettering’s 47th annual academic convocation.
Alexander Drilon, MD
Following an approval from the FDA in May 2020, the New England Journal of Medicine has published data from the phase I/II LIBRETTO-001 clinical trial of selpercatinib in advanced RET (REarranged during Transfection)-driven lung and thyroid cancers. MSK’s Alexander Drilon, MD, the recently appointed Chief of the Early Drug Development Service, serves as the lead investigator for multi-site clinical trial.
Memorial Sloan Kettering medical oncologist Santosha Vardhana with medical mask on.
MSK experts acted quickly to understand the possible effects of COVID-19 on cancer patients and drew on vast experience to explore new treatments.
Participants in Cycle for Survival
Treating Rare Cancers
Memorial Sloan Kettering physicians have experience and specialized expertise in caring for people with uncommon cancers.
Dr. Joan Massagué, Sloan Kettering Institute Director received the Pezcoller Foundation-AACR International Award for Cancer Research and was named an AACR fellow at AACR16.
Announcement
Long-awaited results of clinical trials testing targeted drugs and immunotherapy combinations were on offer at the annual American Association for Cancer Research (AACR) conference.
Leptomeningeal metastasis, cancer that has spread to the areas surrounding the brain and spinal cord, has long been a formidable clinical challenge for oncologists. Researchers at Memorial Sloan Kettering Cancer Center have identified the molecular basis of this increasingly prevalent complication of cancer. With the help of a mouse model, researchers have identified a drug strategy that may combat this virtually untreatable condition. This research by Joan Massagué, PhD, Adrienne Boire, MD, PhD, and colleagues, was published in the March 9, 2017 issue of Cell. For more information on this work and to speak with the study authors, contact [email protected].
Jedd Wolchok and Charlotte Ariyan in the lab
In the Clinic
A new approach for treating melanoma combines the immunotherapy drug ipilimumab with chemotherapy that treats only the area affected by cancer.